Sign in Subscribe

Topic

CPIC

A collection of 132 issues

CPIC Guideline for NAT2 Genotype and Hydralazline Therapy

The CPIC Guideline for NAT2 Genotype and Hydralazine Therapy has been published in the journal Clinical Pharmacology and Therapeutics. This new guideline summarizes and evaluates literature evidence regarding the impact of genetic variants on NAT2's metabolism of hydralazine, a vasodilator typically used in the treatment of resistant hypertension

UPDATE: CHANGE IN DATE for ClinPGx/CPIC/PGRN meeting

The ClinPGx/CPIC/PGRN meeting will now start on Wednesday, September 10, 2025 and end on Friday afternoon, September 12, 2025 in Missoula, Montana. (Change of start date due to airport closure for repaving of their one runway which happens every 20 years in Missoula, Montana.) We anticipate holding a

Save the Date for ClinPGx/CPIC/PGRN 2025

The ClinPGx/CPIC 2025 Meeting will be held in collaboration with the PGRN in Missoula, Montana, September 8-11, 2025.

New must-test alleles for DPYD

The recently published article DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics

Update to the CPIC Guideline for Thiopurines Regarding Dual TPMT and NUDT15 Intermediate Metabolizers

CPIC has updated guidance for patients who are both TPMT and NUDT15 Intermediate Metabolizers from "Clinical Pharmacogenetics Implementation Consortium Guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update". From the CPIC website: "At the time of guideline publication, the extent of reduction for thiopurines

ClinPGx 2024 Registration and Abstract Submission Open

REGISTRATION OPEN In collaboration with CPIC, PharmGKB, PharmCAT and PharmVar, the Penn Institute for Biomedical Informatics will be hosting the ClinPGx 2024: Knowledge, Implementation, Education meeting on June 20th and 21st, 2024 in Philadelphia, PA. This meeting will provide educational content to cover all aspects of PGx implementation, including knowledgebases,

CPIC Guideline for Potent Volatile Anesthetic Agents and Succinylcholine - RYR1 variant update

The original guideline, supplement, and the supporting gene and drug files are available on the CPIC website. Annotations of the guideline, including an interactive genotype picker tool are available on the PharmGKB website. Subsequent to the publication of the CPIC Guideline for the Use of Potent Volatile Anesthetic Agents and

Please Take This Survey If Your Site Conducts DPYD Genetic Testing Prior to Fluoropyrimidine Chemotherapy

Dan Hertz (DLHertz@med.umich.edu) and the DPYD Implementation Team are collecting information from sites and clinicians in the USA that conduct DPYD genetic testing prior to fluoropyrimidine chemotherapy treatment. If this applies to you, please complete this brief (<5 minutes) survey on behalf of your site before

ClinPGx Sessions at PGRN 2023 Conference and ClinGen Summer Workshops

At the upcoming PGRN 2023 annual conference in Memphis, Dr. Teri E. Klein, the principle investigator for PharmGKB, ClinGen, CPIC and PharmCAT, will hold a town hall discussion on ClinPGx: a single integrated resource for Pharmacogenomics (PGx). Dr. Klein will discuss the challenge of the separation of pharmacogenomic resources from

CYP3A5 genotyping is a more accurate predictor of drug response than race alone

A new paper in Journal of Clinical Pharmacology from a group at Indiana University [PMID:37042314] implemented genotyping for CYP3A5 in a kidney transplant center. The team used CPIC guidelines for tacrolimus dosing based on CYP3A5 genotype. Implementation included provider education and clinical decision support in the electronic medical record.